Correct on both counts. P results will be a c
Post# of 72444
Posted On: 02/18/2016 3:04:42 PM
Re: takingabath #18757
Correct on both counts.
P results will be a classic biotech binary event. The drug worked amazingly in animal studies, and if that holds true in this recent human trial, it will change the fortunes of CTIX dramatically, but it could also end up being a complete dud that will leave a mark in the short-term. I do think (for various reasons) that the upside reward for our share price stemming from successful results would be multiples bigger than the downside risk if there is a failure. So 50/50 chance it works or it doesn't, but good results would have a disproportionately bigger impact than bad results, imo.
And ASCO is not a guarantee. We've presented there multiple years in a row, and with funding needs still out there, I'd think we'd like to leverage such an opportunity to market our lead cancer drug, and have to believe Leo and crew will do whatever it takes to make it to that forum. Certainly have a lot more data collected over the past year (since last ASCO) that would be worthy of discussing. Time will tell, but odds are good, I think.
P results will be a classic biotech binary event. The drug worked amazingly in animal studies, and if that holds true in this recent human trial, it will change the fortunes of CTIX dramatically, but it could also end up being a complete dud that will leave a mark in the short-term. I do think (for various reasons) that the upside reward for our share price stemming from successful results would be multiples bigger than the downside risk if there is a failure. So 50/50 chance it works or it doesn't, but good results would have a disproportionately bigger impact than bad results, imo.
And ASCO is not a guarantee. We've presented there multiple years in a row, and with funding needs still out there, I'd think we'd like to leverage such an opportunity to market our lead cancer drug, and have to believe Leo and crew will do whatever it takes to make it to that forum. Certainly have a lot more data collected over the past year (since last ASCO) that would be worthy of discussing. Time will tell, but odds are good, I think.
(0)
(0)